Invesco’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Invesco’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,051	Closed	-$40.8K	–	3994
2023 Q1	$40.8K	Buy	16,051 +5,501	+52%	+$10.9K	﹤0.01%	3771
2022 Q4	$19.7K	Buy	+10,550	New	+$26.3K	﹤0.01%	3973
2022 Q2	–	Sell	-18,211	Closed	-$54K	–	4188
2022 Q1	$54K	Buy	18,211 +765	+4%	+$2.88K	﹤0.01%	3926
2021 Q4	$79K	Sell	17,446 -1,038	-6%	-$4.92K	﹤0.01%	3929
2021 Q3	$90K	Buy	18,484 +3,950	+27%	+$21.8K	﹤0.01%	3954
2021 Q2	$99K	Buy	+14,534	New	+$118K	﹤0.01%	3895
2020 Q4	–	Sell	-142,486	Closed	-$771K	–	3842
2020 Q3	$771K	Buy	+142,486	New	+$706K	﹤0.01%	2932
2017 Q4	–	Sell	-152,754	Closed	-$3.83M	–	3675
2017 Q3	$3.83M	Sell	152,754 -191,645	-56%	-$4.46M	﹤0.01%	2135
2017 Q2	$8.3M	Buy	+344,399	New	+$7.61M	﹤0.01%	1658
2015 Q3	–	Sell	-1,415	Closed	-$36K	–	4047
2015 Q2	$36K	Buy	+1,415	New	+$40.1K	﹤0.01%	4001

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Invesco's PRTK Position: Q2 2023 in Review

Invesco sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 16,051 shares — an estimated $40.8K sold.

Invesco first reported a position in PRTK in Q2 2015 and held it in 10 quarters. The position peaked at $8.3M in Q2 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Invesco reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Invesco sold 16,051 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $40.8K.
Invesco first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Invesco's Paratek Pharmaceuticals, Inc. position peaked at $8.3M in Q2 2017.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.